XFOR Earnings

XFOR reported its FY2024Q4 earnings on 2025-03-25, showcasing a revenue of 1.00M against an estimate of 1.00M, resulting in a 34.69% surprise. The EPS was -0.2, surpassing the expected -0.17 by -17.65% . The stock experienced a -12.07% price change on the earnings day and a -19.86% change over the next five days, reflecting market reactions to the results.

Following XFOR's FY2024Q4 earnings announcement on 2025-03-25, the stock price moved by -12.07% on the day of the release. Over the subsequent five days, it saw a -19.86% change. Historically, XFOR's stock price tends to shift by an average of +9.66% in the 10 days leading up to earnings and +0.85% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate XFOR’s annual revenue to reach 2.00M, while the EPS is projected at -4.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between XFOR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, XFOR's stock price typically moves by +9.66% in the 10 days before its earnings and +0.85% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of -4.00 and revenue of 2.00M.

The earnings call presents a mixed picture. Financially, the company is stable with $90 million in cash and a strategic spending reduction plan. However, sales are modest, and there are concerns about supply chain challenges and competitive pressures. The reverse stock split and lack of clear guidance on patient dropout rates in trials could raise investor caution. The Q&A revealed strong demand and patient compliance, but management's vague responses on certain metrics may worry analysts. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.